Category Archives: General Cynicism

Pharmaceuticals Profitability makes Walmart feel Sick

Compare the revenues and profits of these companies : (Data from Fortune 500 2010)


Medicynical Note: Using profits as a percent of total revenue the pharmaceutical industry may well be the most profitable sector in the Fortune 500. For example, Walmart offers a paltry 3.51% of revenue as profit, Exxon 6.77%, Apple a mere 15.6%. Drug companies and these are not the foreign based big earners garner Johnson and Johnson 19.8%, Pfizer 17.6%, Merck 47.2% and Abbott 19.1%, Lilly 19.8%, Bristol-Meyer Squibb 49.05%.

You gotta feel sorry for the poor drug companies. Guess who pays?


Glioblastoma–We Need Better Treatments, but can we afford them?

Our non-system of care’s great virtue, we’re told, is that the profit motive encourages development of new approaches. The problem is that the profit and costs in our cost plus system of reimbursement are so great that the system and individuals can’t afford the new “advances”–which by the way are mostly of marginal benefit.

For the past thirty years in oncology we’ve been combining therapies to improve outcomes. When each of the drugs in combination cost under $1000/month, such combinations were doable. While expensive for the time, their cost does not compare with the current situation of drugs costing $10,000/month and more.

One example of what’s happening is in the treatment of glioblastom multiforme, the most malignant tumor of the brain, the disease from which Teddy Kennedy succumbed. Standard treatment used to be radiation with or without chemotherapy. Until recently the chemo was older agents that were moderately priced. With the advent of Temodar a few years ago costs have spiraled.

He will need to take 140 mg of temozolomide (75 mg/m2 per day) for 42 consecutive days. Each 140-mg capsule of temozolomide costs $283.32 ($1416.59 for 5 capsules) and the total for 42 capsules is $11,899.44. For the first cycle of metronomic temozolomide (5 days at 150 mg/m2 per day), the patient will need to take 2 of the 140-mg capsules daily for a total cost of $2833.20. For subsequent cycles of metronomic temozolomide (200 mg/m2 per day), the patient will need to take one 250-mg capsule, one 100-mg capsule, and one 20-mg capsule each day for 5 days. The prices for 5 each of the 250-mg, 100-mg, and 20-mg capsules, respectively, are $2334.29, $933.70, and $186.71. The total cost for each 5-day cycle of metronomic temozolomide at 200 mg/m2per day is therefore $3454.70.

If the same patient experiences GBM recurrence, his chemotherapy may be changed to bevacizumab and irinotecan. He will need 10 mg/kg of bevacizumab every 2 weeks. At 155 pounds, he is roughly 70 kg, so he will need 700 mg of bevacizumab. The cost of bevacizumab is $687.50 per 100 mg, so the cost of each infusion will be $4812.50.

Medicynical Note: Remember, each of these costs is for the drug alone. Additional expenses include physician’s fees, imaging costs (MRI’s, etc), other medications and nursing support.

Temozolomide has limited benefits:

Median survival in the radiation-plus-temozolomide group was 14.6 months, compared with 12.1 months in the radiation-only group. After two years, 26.5 percent of patients in the radiation-plus-temozolomide group were alive, compared with 10.4 percent of those who received radiation only. After 5 years, 9.8 percent of patients in the radiation-plus-temozolomide group and 1.9 percent of those in the radiation-only group were still alive.

And in Lancet 2009:

278 (97%) of 286 patients in the radiotherapy alone group and 254 (89%) of 287 (Medicynical note: patients who died over 5 years)

Regarding bevacizumab in glioblastoma, its use is based on small non randomized studies:

One of the trials (known as AVF3708g, or BRAIN) involved 167 patients with glioblastoma who had progressed on radiation and temozolomide (Temodar, Schering) and who then received bevacizumab either alone or in combination with irinotecan. According to an FDA analysis of the study, tumor responses were observed in 22 of 85 patients (26%) treated with bevacizumab alone, and the median duration of response was 4.2 months. (note: that’s a response in just 22 patients. The others were treated, 63 patients and had no benefit whatever)

In another trial (NCI 06-C-0064E), 56 patients with recurrent glioblastoma were treated with bevacizumab alone. Responses were observed in 11 patients (20%), and the median duration of response was 3.9 months. (Note: that’s a response of 3.9 months in the 11 patients who responded. None of the 45 other patients benefited)

There are no data so far from randomized trials for overall survival.

Medicynical Note: The question is can any system afford drugs costing tens of thousands of dollars/month? Can it afford such drugs in non curative situations? Can it afford using two such drugs simultaneously or in sequence if they provide temporary benefit for just a few of the patients treated?

Should we revisit how we develop new drugs? Revise patent law to encourage efficiency and affordability? Factor in cost efficiency when approving drugs? Consider whether our current system of granting generation long monopolies on new drugs is in the best interest of patients? Or the system?

It’s amazing but we have developed a system of drug development that is unaffordable, inefficient, and doomed.


The Tyranny of Expectations–Health Care and it’s Reform

We pay more for care than anywhere else in the world.




Our doctors are among the highest paid in the world




Source: Congressional Research Service (CRS) analysis of Remuneration of Health Professions, OECD Health Data 2006 (October 2006), available at [http://www.ecosante.fr/OCDEENG/70.html].
Source: Congressional Research Service (CRS) analysis of Remuneration of Health Professions, OECD Health Data 2006 (October 2006), available at [http://www.ecosante.fr/OCDEENG/70.html].

Our medical care, administrative, drugs and medical technology costs are also the highest in the world. This from economix:

One thing Americans do buy with this extra spending is an administrative overhead load that is huge by international standards. The McKinsey Global Institute estimated that excess spending on “health administration and insurance” accounted for as much as 21 percent of the estimated total excess spending ($477 billion in 2003). Brought forward, that 21 percent of excess spending on administration would amount to about $120 billion in 2006 and about $150 billion in 2008. It would have been more than enough to finance universal health insurance this year.

The study used a measure of administrative costs that includes not only the insurer’s costs, but also the costs borne by employers, health-care providers and governments – but not the value of the time patients spent claiming reimbursement. These authors estimated that in 1999, Americans spent $1,059 per capita on administration compared with only $307 in purchasing power parity dollars (PPP $) spent in Canada.

These expenses have to do with expectations:

  • Patients expect care: Price should not be an issue, at least to them. These expenses have been buffered by private insurance, government programs, and to a lesser degree our altruism (mandatory access to ER care in emergencies).
  • Health care providers also have expectations: They went to great expense and time to go through training and many have huge debts to repay. Their expectation is that they earn an excellent living.
  • Medical Insurers expect that they will keep 20% of premiums for their services–contributing to the highest administrative expenses in the world–and million dollar salaries and benefits for their executives
  • Medical suppliers, pharmaceutical companies: Huge international corporations also have high profit expectations. Patent laws provide exclusivity for a generation. Drugs are priced not by their cost of development or manufacture but whatever the market will bear. So those with serious illness pay more–because they have to.
  • Cost Efficiency is an oxymoron in our non-system: When you have a life-threatening illness cost, efficiency and “shopping” for the best deal are not priorities. Unfortunately, efficacy gets lost in the mix and patients and their insurers, (honoring the patient’s desires) pay exorbitant premiums for treatments that often offer very limited benefit.

Medicynical Note: Expectations and money:

It would seem a given in this the wealthiest (I think that still is the case) economy in the world that health care should be accessible and affordable to all. That is certainly the case in other industrialized nations.

Industry has figured out that health care is not cost sensitive. Why be efficient when the system will pay whatever is demanded. Patients are in a bind and buffered by third party payers; doctors earn more by doing more; industry charges cost plus at every level. Our health care system has become the moral equivalent of the Air Force’s $600 toilet multiplied 100 fold. We now spend more for a single drug than the average and median income–amazing.

One would think that with all this spending everyone would have some coverage, but it’s a fact that we have 50 million uninsured and still spend more per capita by a wide margin than anywhere else in the world.


Every man/woman for him/herself–the opposition to health reform

It’s fascinating to watch the public reaction to health reform.

It was a very difficult byzantine process complicated by the republican do nothing attitude and very unpleasant legislative maneuvering.

But what’s astounding and revealing is the public’s lack of enthusiasm which ultimately may doom the whole process.

Consider the situation.

  • Health care is not absolutely essential at any given time in most people’s lives–most of us are healthy and simply do not understand the difficulties and costs incurred of those who are.
  • And anyway most of us, have some form of health coverage. Those with coverage wonder what reform will offer them.
  • Reform will certainly add to the complexity and who knows whether it will add to our costs.
  • There are a large number of people in our country, around 50 million, with no coverage at all. In this group most are quite healthy and aside from an occasional visit to a doctor have few needs.
  • Those without health insurance either deny the possibility of illness or count on their savings, if they have any, or public payments in one form or another for their catastrophic illness care.
  • Preventive medicine is an unnecessary unaffordable, for the most part, luxury for these people.

Health reform rocks the boat and requires most of the “uninsured” to have coverage. I believe it will ultimately cut costs but can understand the skepticism. Our long national history of exceptionalism makes these folks unwilling to consider that health reform might be a positive. To them it’s a mandated enforced expenditure, a tax on their hard earned money.

On the other side of the argument are facts that:

  • Every single one of us, sooner or later will require medical care.
  • Health care spending over a lifetime is our largest expense.
  • To have rational system in which insurers provide coverage to those with illness and to prevent gaming of the system (only getting coverage when you become sick) universal coverage is necessary.
  • Costs will have to go down as we cannot afford our current health care expenditures and yearly inflation. Efficiency and value are concepts that must be applied to health care, like other business ventures.
  • Our current non-system of mandating access to emergency rooms for free care is inefficient, medically unsound and extremely expensive–guess who pays?
  • The more people covered the lower the premiums and ultimately the lower the costs
  • Our health outcomes are mixed. In some areas we do as well as other countries in others our outcomes are significantly worse.
  • Preventive medicine is underutilized in our system by those who need it most, the poor and the uninsured–ultimately tax payers pay their emergency room costs and other associated medical expenses.

Somewhere along the way Americans lost the notion of community and replaced it with a nasty NIMBY attitude. Companies, farmers, bankers and many other businesses baldfacedly accept and encourage all manner of subsidies, price supports, and bailouts that keep their business solvent. The idea that a benefit be available to individuals however, is “socialistic” and “un-American.”

That’s hardly the case since for the last 70 years we and our economy have benefitted and had wonderful years of growth and prosperity in a system with numerous social support programs. Abandoning these principles for a non-system in in which it’s every man for him/herself is a non plan leading nowhere. And that’s exactly where we’ll be if health reform is repealed.


Costs–why we pay more!

This is from Economix–quoting Dr. David Cutler:



Medicynical Note: For every doctor there are 5, countem, five administrative and office support staff–and that doesn’t count another 500,000 “management” types. Guess who pays?


Cost Consciousness in Health Care: Value Value

This from the New England Journal of Medicine in an article by Molly Cooke:

It is old news that the cost of medical care in the United States is unsupportable, yet we seem unable to grapple with the issue effectively. As current ideas for health care reform have percolated through Congress, cost-control mechanisms have generally been recognized as the weak component. Our country is remarkably generative in the development of new diagnostic tests, drugs, and procedures — and remarkably undisciplined in their deployment. New diagnostic and therapeutic procedures and the broadened application of established ones account for two thirds of the growth in health care expenditures.

Cooke believes medical schools and teaching institutions have a responsibility to teach cost consciousness in health care. Such a responsibility would seem natural given that health care is the largest expense of many people’s lifetime.

But:

Philosophically, we physicians have conceived of ourselves as, and taught students that we are, advocates for each patient, obligated to eschew all considerations other than benefit to that patient and his or her preferences.

And:

A predominant driver of the cost of hospital care is the length of stay, so a high priority is readying patients for discharge — which serves as a rationale for preemptively ordering any test and consultation that might be called for, to avoid delaying discharge. Consequently, students and residents have scarce opportunity to practice devising cost-effective diagnostic strategies and explaining their rationale to patients and families.

And

Finally, cultural values powerfully influence the selection of teaching topics. Academia celebrates the “high knowledge” of medicine: pathophysiology, molecular biology, genomics. Even evidence-based medicine, although it deemphasizes fundamental mechanisms, is regarded as acceptably intellectual in comparison with “low,” real-world concerns such as cost.

Medicynical Note: Teaching cost consciousness would apprear to be a no brainer given the near 17% of GDP spent on health care, the excessive costs of health care in the U.S. compared with elsewhere, the high medical related bankrupcy rate in our country, and our yearly excessive increase in health care costs. The article goes on to point out the urgent need to change and to value value!


Myeloma Survival–How much better? and can we afford it?

Jane Brody in today’s Times talks of the improvement in survival in multiple myeloma.

She notes there has been marked improvments in survival.

My guarded optimism stems from the progress made in devising treatments for several less well-known malignancies. For many patients with cancers like chronic lymphoma, chronic myelocytic leukemia and now multiple myeloma, longevity lies in the ability of science to remain one step ahead of the malignancy by unraveling its genetic and molecular underpinnings and producing treatments tailored to counter them.

How good is good?

The analyses found a definitive overall increase in the survival of MM patients over the past decade. In particular, five-year survival increased from 28.8 to 34.7 percent, and 10-year survival increased from 11.1 to 17.4 percent. Importantly, survival increased most dramatically in the youngest age group — more than half (56.7 percent) of patients younger than 50 survived at least five years, and more than 40 percent (41.3 percent) survived at least 10 years. In real years, the average relative survival increased from four years after diagnosis in 1990-1992 to almost seven years after diagnosis in 2002-2004.

Patients age 50-59 also fared well, with approximately half (48.2 percent) surviving at least five years, and nearly a third (28.6 percent) surviving at least 10 years. However, only modest increases were seen in the age group 60-69, and virtually no improvement was seen in patients older than 70. Since about half of MM patients are diagnosed when they are 60 or older, the lack of improvement in the eldest groups is a critical finding of the research.

Medicynical note: There are two problems with Brody’s analysis. First as noted in the latter review of progress there has been “modest” improvement for those age 60-69 and no improvement in patients older than 70. FYI the median age of myeloma patients is 66 with just 2%, thankfully, under age 40. Secondly, the cost of new treatments is excessive. The treatments recommended are in the range of $50,000-$100,000/year or more for the drugs alone and multiples of $100,000 for the transplants. This in a disease in which 5 year survival has “improved” to 34%.

Yes, there has been progress but it’s been mainly limited to younger patients and is at tremendous cost. We need to find a way to be more efficient and provide better value.


Why we pay more for health care!?

Pricing of health care in Massachusetts was analyzed by the Attorney General of that state. She found:

A. Prices paid by health insurers to hospitals and physician groups vary significantly within the same geographic area and amongst providers offering similar levels of service.

B. Price variations are not correlated to (1) quality of care, (2) the sickness of the population served or complexity of the services provided, (3) the extent to which a provider cares for a large portion of patients on Medicare or Medicaid, or (4) whether a provider is an academic teaching or research facility. Moreover, (5) price variations are not adequately explained by differences in hospital costs of delivering similar services at similar facilities.

C. Price variations are correlated to market leverage as measured by the relative market position of the hospital or provider group compared with other hospitals or provider groups within a geographic region or within a group of academic medical centers.

D. Variation in total medical expenses on a per member per month basis is not correlated to the methodology used to pay for health care, with total medical expenses sometimes higher for risk-sharing providers than for providers paid on a fee-for-service basis.

E. Price increases, not increases in utilization, caused most of the increases in health care costs during the past few years in Massachusetts.

F. Higher priced hospitals are gaining market share at the expense of lower priced hospitals, which are losing volume.

G. The commercial health care marketplace has been distorted by contracting practices that reinforce and perpetuate disparities in pricing.

Medicynical Note: Why do we pay more? Because our health care system is not a system. It’s a mechanism for manipulation and wealth accumulation not health care.


DNA not patentable!

Always thought patenting DNA sequences was the most outrageous abuse of the patent system, until drug companies charged more than the median and average income for a single drug.

Medicynic: It was as outrageous as the Supreme Court overturning a lower court to provide “free speech” rights to corportations by removing limits on campaign contributions. Hopefully they don’t overturn this!


What wrong here?

Costs continue to increase, this year we spent 17.3% of GDP on healthcare. But incomes are declining.

Medicynical Note: Those thinking our non-system is the best in the world should be informed that is isn’t and isn’t sustainable either. Hopefully health reform will affect the cost spiral–is it a bubble?